BALY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Bally's Corp is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to allocate. The stock has weak analyst support, no recent positive news catalysts, no meaningful insider or congress buying, and the technical setup is only neutral-to-mildly constructive rather than strongly bullish. Since the user wants a direct answer and is not looking to wait for a better entry, my clear view is to avoid buying now and wait for a stronger fundamental turnaround and more convincing price action.
BALY is trading at 14.82, slightly above its pivot at 14.041 and below resistance at 15.286. MACD histogram is positive at 0.178 but contracting, which suggests momentum is fading rather than accelerating. RSI_6 at 65.608 is near the upper end of neutral and does not offer a clear oversold entry. Moving averages are converging, indicating a lack of strong trend confirmation. Overall, the chart is range-bound to mildly bullish in the very short term, but not strong enough to justify a long-term buy for a beginner.
No news was reported in the recent week, so there are no visible event-driven catalysts. The stock is still above its pivot level, and the MACD histogram remains positive, which are modest near-term supportive signs. Stifel recently raised its target to $13 from $12, showing that not all analyst views are deteriorating, although the rating remains Hold.
Analyst sentiment has been mixed to negative: Barclays cut its target to $8 and kept Underweight, Macquarie lowered target to $15, Stifel lowered then only slightly raised its target while keeping Hold, and Truist highlighted limited liquidity and elevated leverage. There is no recent news flow to support upside, no notable insider buying, no significant hedge fund accumulation, and no recent congress trading activity. The stock trend model also points to weak forward performance over the next week and month.
No usable latest-quarter financial snapshot was provided because the financial data returned an error. Based on the analyst commentary, the latest reporting period appears to have reinforced concerns around liquidity, leverage, financing needs, and project execution rather than showing clear growth acceleration. The most recent quarter season could not be confirmed from the data provided.
Recent analyst revisions are mostly cautious: Barclays cut the target to $8 with an Underweight rating, Macquarie reduced its target to $15 with Neutral, Stifel lowered to $12 and kept Hold before later raising to $13 but still Hold, and Truist cut to $13 while keeping Hold. The Wall Street pros view is largely cautious-to-bearish because of leverage, liquidity, and development risk. The main con view is stronger than the pro view, and there is no broad upgrade trend suggesting a durable bullish re-rating.
